Education and Training
Fragmin for the Treatment of Acute VTE in Pediatric Cancer Patients
Three month treatment of acute VTE with Fragmin in pediatric cancer patients
Stanford is currently not accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: dalteparin
Eligibility
Inclusion Criteria:
-
Exclusion Criteria:
-
Ages Eligible for Study
N/A - 18 Years
Genders Eligible for Study
All
Not currently accepting new patients for this trial
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Peds Hem/Onc CRAs
650-723-5535
Not Recruiting